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Genome sequence analysis of HIV-1 subtype C viruses from India shows monophyletic lineage and relatively limited genetic diversity. To
understand its immunological implication, cross-reactivity of neutralizing antibody response was investigated. In primary screening, neutralizing
antibody response to single heterologous primary HIV-1 subtype C isolate was assessed in plasma samples from 235 HIV-1 infected, anti-
retroviral treatment naive individuals from Pune, India. Plasma samples that showed ≥90% neutralization and two randomly selected plasma
samples that showed 50–60% neutralization were tested against a panel of primary HIV-1 subtype C isolates obtained from epidemiologically
unlinked individuals from India. The neutralizing antibody response showed extensive cross-neutralization, suggesting presence of shared
neutralization determinants among circulating HIV-1 subtype C viruses in India.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV subtype C; India; Cross-neutralization; Genetic diversityIntroduction
HIV-1 subtype C has several unique properties such as
predominance of R5 phenotype even in patients with advanced
disease (Cecilia et al., 2000), relatively conserved V3 loop
(Gaschen et al., 2002), three Nuclear Factor (NF)-κB binding
sites in Long Terminal Repeats (LTR) (Choudhury et al., 2000)
and resistance to neutralization by human monoclonal anti-
bodies 2G12 and 2F5 that show broad neutralizing activity
against HIV-1 non-subtype C isolates (Binley et al., 2004).
Shankarappa et al. (2001) reported that HIV-1 subtype C
nucleotide sequences of V3–V4 region of env from India were
closely related to each other. Our studies on HIV-1 env (gp120
and gp41), gag and nef have also shown that HIV-1 subtype C
nucleotide sequences from India form monophyletic lineage
(Agnihotri et al., 2004, 2006; Jere et al., 2004; Kurle et al.,
2004). Similar results were obtained by analysis of available
full-length genome sequences from India (Novitsky et al., 1999,⁎ Corresponding author. Fax: +91 20 27121071.
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doi:10.1016/j.virol.2006.09.0192002). These observations point towards limited genetic
diversity among Indian HIV-1 subtype C viruses.
Limited genetic diversity may have important immunologi-
cal advantage. There may be greater sharing of epitopes among
the circulating viruses. Therefore, immune response induced
against one strain may extensively cross-react with the other
strains. In a study of HIV-1 subtype C infected individuals from
South Africa (Bures et al., 2002), broadly cross-reactive
neutralizing antibodies were detected along with neutralizing
antibody response to autologous virus. Based on this observa-
tion, the authors suggested that HIV-1 vaccine might have to
overcome less epitope diversity in South Africa.
Studies of HIV-1 specific Cytotoxic T Lymphocyte (CTL)
response in Indian patients (Paranjape et al., 1998; Thakar et
al., 2002) showed cross-reactive CTL response and presence
of conserved immunodominant regions in HIV-1 subtype C
Gag and Nef (Thakar et al., 2005). This finding is consistent
with the hypothesis that there is extensive sharing of epitopes
within HIV-1 subtype C viruses in India. Generating such
data is likely to be important in the context of development of
prophylactic HIV-1 vaccine. However, there is paucity of data
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in HIV-1 subtype C infected individuals from India.
We investigated neutralizing antibody response developed
by HIV-1 infected individuals against multiple heterologous
subtype C isolates obtained from epidemiologically unlinked
patients from India.
Results
Primary screening for HIV-1 neutralizing activity of plasma
derived from HIV-1 seropositive individuals
Plasma samples from 235 HIV-1 seropositive individuals
obtained during years 2001 to 2003 from Pune (Maharashtra),
India were tested against a heterologous, primary HIV-1
subtype C isolate (VB 49). The VB 49 was isolated from
HIV-1 seropositive individual from Pune, India in year 1999.
All plasma samples were tested at 1/10 dilution for HIV-1
neutralizing activity using GHOST cell assay as described
earlier (Trkola et al., 1998). Out of 235 samples, 19 (8%)
showed ≥90% neutralization (≥1 log reduction in infectivity)
of VB 49, whereas 51 (21%) showed neutralization in the range
of 50 to 89%. Remaining samples showed <50% neutralization.
Background response shown by 20 plasma samples from
healthy, HIV seronegative individuals at this dilution was 5.8±
8.3% (mean±SD).
Neutralizing activity was not found to be associated with
CD4+ T cell count, plasma viral RNA level and clinical status
(data not shown).
Neutralizing antibody response showed extensive
cross-reactivity against heterologous viruses isolated from
epidemiologically unlinked individuals
Nineteen plasma samples that showed ≥90% neutralization
in primary screening were tested against a panel of 13 primary
HIV-1 isolates (including the virus isolate used in primary
screening). The isolates were obtained from epidemiologically
unlinked (as per our knowledge) individuals residing in four
different states of India and were isolated between year 1999
and 2005 (Table 1). Serial two-fold dilutions of each plasma
sample were tested against each HIV-1 isolate for neutralizing
activity using GHOST cell assay.
Extensive cross-neutralization of heterologous viruses sug-
gesting presence of shared neutralization determinants among
viruses circulating in India was observed (Table 1). Table 1
presents highest plasma dilution that showed 50% neutraliza-
tion (ID50) of thirteen virus isolates from the test panel. We have
also shown plasma-virus reactions where ≥90% neutralization
was observed (Table 1) as≥90% neutralization is likely to have
more biological relevance (Mascola, 2003; Nishimura et al.,
2002). The negative control (PNP: Pooled Normal Plasma from
12 healthy, HIV seronegative individuals) tested at 1/10 dilution
showed <30% background response in all the assays.
In Table 1, we have organized viruses in decreasing order of
neutralization sensitivity (based on geometric mean ID50 shown
against all plasma samples) and plasma samples in decreasingorder of neutralization capacity (based on geometric mean ID50
against all HIV-1 isolates). Geometric mean ID50 against 19
plasmas ranged between 17.7 for BH 9390 and 160.0 for VB 39.
Conversely geometric mean ID50 against 13 viruses ranged
from 14.1 for CPI 218 to 201.6 for CPI 177.
Out of 19 plasma samples, 7 samples (CPI 177, 220, 267,
243, 287, 255, 261) showed ≥90% neutralization against
majority of isolates (≥11) and ≥50% neutralization against all
isolates from test panel. Eight plasma samples (CPI 229, 91,
244, 294, 223, 212, 133, 214) showed≥90% neutralization of 5
to 10 isolates and ≥50% neutralization against >10 isolates
from test panel. Three plasma samples (CPI 158, 153, 99)
showed ≥90% neutralization of 1 to 3 isolates and ≥50%
neutralization against 7 to 11 isolates from test panel.
Remaining plasma sample (CPI 218) showed ≥50% neutraliza-
tion against four isolates (Table 1).
Since there are multiple neutralization determinants for HIV-
1, heterologous viruses that are more close to autologous virus
may be neutralized at higher titer compared to more distant
viruses. This may be evidenced by ID50 value against given
isolate. Comparison of the ID50 values shown by the 19 plasma
samples against virus isolates from Maharashtra (state from
where all plasma samples were obtained) and virus isolates
obtained from other states (Karnataka, Goa, Delhi) showed that
cross-neutralization was irrespective of origin of viruses.
Additionally two plasma samples (CPI 129 and CPI 194) that
showed 50–60% neutralization in primary screening (against
isolate VB 49) were randomly selected and tested against panel
of 8 primary HIV-1 isolates (subset of above described 13 HIV-
1 isolates). These samples showed >50% neutralization of 6 and
4 isolates (out of 8) respectively (Fig. 1). These samples showed
>30% neutralization (mean+3 SD inhibition shown by plasma
from 20 healthy HIV uninfected individuals against one primary
HIV-1 isolate) in all (except one) reactions. This suggests that
the presence of cross-reactive neutralizing antibody response is
not restricted to plasma samples that showed ≥90% neutraliza-
tion in primary screening.
Analysis of HIV-1 subtype C env (gp120) nucleotide sequences
revealed that sequences from India show limited genetic
diversity compared to other subtype C prevalent countries
We investigated diversity among HIV-1 env (gp120) nucleo-
tide sequences from India, Burundi, Botswana, South Africa,
Tanzania and Zambia. The sequences were selected by using
“one sequence/patient”mode at the interface of NIHLos Alamos
HIV sequence database (http://hiv-web.lanl.gov/components/
hiv-db). There were 17 sequences from India, 8 from Burundi,
51 from Botswana, 180 from South Africa, 15 from Tanzania
and 10 from Zambia. All sequences from India, Burundi,
Tanzania, Zambia and 17 randomly selected sequences from
Botswana and South Africa were analyzed for genetic diversity.
The pairwise % genetic divergence was determined using
MegAlign program (DNASTAR Inc). The mean±SD and
median genetic divergence (%) of all pairwise sequence
comparisons was 9.9±2.3 and 10.0 for India, 12.1±1.3 and
11.9 for Burundi, 15.0±1.2 and 14.9 for Botswana, 15.2±1.9
able 1
50 shown by plasma samples (that showed ≥90% neutralization in primary screening) against thirteen isolates
haded box represents ≥50% neutralization. <10 represents <50% neutralization at 1/10 plasma dilution. PNP: Pooled Normal Plasma (negative control).
lasma samples were collected during year 2001–2003 from Pune (Maharashtra), India.
IV-1 isolate used for primary screening.
aharashtra.
arnataka.
Plasma–virus reaction where ≥90% neutralization was observed at 1/10 plasma dilution.
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Fig. 1. Cross-reactivity of plasma samples selected for 50–60% neutralizing
activity. Two plasma samples (CPI 129 and CPI 94) showing 50–60%
neutralizing activity against one primary HIV-1 isolate (VB 49) were tested
against panel of primary HIV-1 isolates (X-axis). Mean+SD obtained in two
independent experiments is presented.
Fig. 2. Diversity among HIV-1 subtype C envelope (gp120) nucleotide
sequences from different countries. The sequences from India show significantly
less diversity (p<0.001) compared to sequences from other countries. Pairwise
% genetic divergence among available nucleotide sequences (one sequence per
patient) was determined by MegAlign program. The boundary of the box closest
to zero indicates the 25th percentile, a solid line within box shows median and
boundary of the box farthest from zero indicates 75th percentile. Whiskers
above and below the box indicate the 10th and 90th percentiles. Outliers for
India and Tanzania are shown by different symbols.
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14.3±1.7 and 14.2 for Zambia. The divergence observed among
sequences from India was significantly low (p<0.001) com-
pared to divergence observed among sequences from other
subtype C prevalent countries (Fig. 2).
Discussion
Several studies suggest limited genetic diversity among
circulating viruses in India. In phylogenetic analysis, most
Indian viruses form compact cluster and probably are
descendent of a single founder strain or limited diversity of
strains introduced at the beginning of the epidemic in India
(Agnihotri et al., 2004, 2006; Eshleman et al., 2005; Gaschen
et al., 2002; Gupta et al., 2005; Jere et al., 2004; Kurle et al.,
2004; Novitsky et al., 2002; Novitsky et al., 1999;
Shankarappa et al., 2001). Constant shifts in glycosylation
sites in envelope protein play important role in protecting
virus from neutralizing antibodies (Wei et al., 2003). During
analysis of envelope protein sequences from India, it was
observed that all potential glycosylation sites were well
conserved (Agnihotri et al., 2004). Due to high degree of
homogeneity in circulating viruses, distinction between
autologous and heterologous neutralization may be blurred.
This may result into extensive cross-neutralization of hetero-
logous viruses. This speculation provoked to investigate cross-
reactivity of neutralizing antibody response of HIV-1 infected
individuals from India. Currently, there is paucity of data
about neutralizing antibody response in HIV-1 infected
individuals from India.
We selected ART-naive plasma samples showing ≥90%
neutralization of a heterologous, primary HIV-1 subtype C
isolate and subsequently tested their ability to neutralize panel
of HIV-1 isolates. These isolates were obtained from epide-
miologically unlinked HIV-1 infected individuals. The indivi-
duals were residents of four different states of India, and the
isolates were obtained at different time points (between year
1999 and 2005). This ensured that viruses used in the study arefrom diverse origin. The samples showing ≥90% neutralizing
activity in primary screening showed extensive cross-neutrali-
zation of multiple isolates (Table 1). The cross-reactivity was
not restricted to samples showing ≥90% neutralization. The
samples showing 50–60% neutralization in primary screening
also showed neutralization of multiple isolates from the test
panel (Fig. 1). The broad range of ID50 values shown by each
plasma sample against different viruses (Table 1) indicate that,
although there may be shared neutralization determinants, each
isolate may also carry a unique set of such determinants. Minor
variations in amino acid sequence of neutralization epitopes can
influence antibody binding affinity and contribute to variability.
Variations in the exposure of neutralization epitopes may also
contribute to differences in the outcome of virus–antibody
interactions. The differential cross-neutralizing activity also
needs to be evaluated in the light of implicit of mixed polyclonal
antibody response.
Since env gene is most relevant in the context of HIV-1
neutralization, we investigated genetic diversity among nucleo-
tide sequences of env gp120 of HIV-1 subtype C viruses from
subtype C prevalent countries. Diversity among sequences from
India was found to be significantly low (p<0.001) compared to
diversity observed among subtype C sequences from Burundi,
Botswana, South Africa, Tanzania and Zambia (Fig. 2). This
supports our hypothesis that extensively cross-reactive HIV-1
neutralizing antibody response among Indian patients may be
attributable to the shared neutralization determinants among
circulating viruses in India. However, considering each virus
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necessary that molecular analysis of this cross-reactivity is
carried out.
Factors that have been discussed to be positively
associated with breadth of HIV-1 neutralizing activity include
high CD4+ T cell count (Carotenuto et al., 1998), exposure to
multiple viruses due to many partners (Bures et al., 2002) and
period after infection (Moog et al., 1997). Out of 19 plasma
samples that were tested against a panel of HIV-1 isolates,
three were from patients with CD4+ T cell count less than 50
cells/mm3. Out of these three samples, two showed marginal
breadth of neutralization whereas remaining sample showed
≥90% neutralization of all thirteen isolates. Three women
participants with a history of single constant HIV-1
seropositive partner (monogamous) showed ≥90% neutraliza-
tion of eight or more isolates from the panel indicating that
the cross-neutralization may not be just consequence of
exposure to diverse virus strains that may occur in multiple
partner setting. These findings discount the possibility that the
above mentioned factors have overwhelmingly contributed to
our interpretations. Date of infection is unknown for all
plasma donors. This limitation makes it difficult to interpret
whether cross-reactive neutralizing antibodies developed
along with response to autologous virus following primary
infection or accumulated over time as reported earlier. A
report on recent seroconverters from India showed that
plasma samples obtained within 1 year of seroconversion
mediate neutralization of heterologous HIV-1 isolates (Kulk-
arni, 2005).
It has been reported that there is selective transmission of
neutralization sensitive viruses (Derdeyn et al., 2004). How-
ever, the isolate 26191 that was obtained from recently infected
individual (within 1 month after seroconversion) did not show
more neutralization sensitivity compared to other viruses that
were obtained from different stages of infection.
Earlier studies based on neutralization of heterologous HIV-1
primary isolates obtained from same cohort or from same
geographic region show that extensive cross-neutralization of
such isolates is exclusive feature of Long Term Non-
Progressors (LTNPs) (Cao et al., 1995; Carotenuto et al.,
1998; Pilgrim et al., 1997; Zhang et al., 1997). Patients with
progression of disease show limited cross-neutralization of
heterologous isolates after few years of infection (Moog et al.,
1997; Wrin et al., 1994). These studies are from countries where
HIV-1 B is the predominant subtype. A study of recently
subtype C infected individuals from South Africa showed that
neutralizing antibody response developed against autologous
virus can also neutralize heterologous South African subtype C
isolates (Bures et al., 2002). This may be due to shared
neutralization determinants among circulating subtype C
viruses in South Africa. This is supported by the observation
that subtype C viruses show less genetic diversity compared to
subtype B viruses (Gaschen et al., 2002). HIV-1 infected
individuals from India showed extensive cross-neutralization of
circulating subtype C viruses from India. The degree of cross-
neutralization and mean neutralization titer was higher
compared to study based on subtype C infected individualsfrom South Africa. This might be due to significantly less
diversity observed in subtype C sequences from India compared
to South Africa (Fig. 1).
Selection of viruses for evaluation of neutralizing antibody
responses induced by various immunogens is a vital concern.
Due to limited genetic diversity, a panel of few immunologi-
cally assorted HIV-1 isolates might be adequate for assessment
of neutralizing antibody responses elicited by various immuno-
gens. Moreover, limited HIV-1 genetic diversity and broad
cross-reactivity of neutralizing antibodies generated in HIV-1
infected individuals from India suggest advantages that may be
explored further for development of prophylactic HIV-1 vaccine
candidates. Immunogen based on the virus that can elicit potent
and broadly cross-reactive neutralizing antibody response might
be a good candidate for further evaluation. Similarly HIV-1
isolate that is amenable to neutralization by majority of sera
indicating presence of consensus neutralization determinants of
circulating viruses can be used for development of new
immunogens. Immune responses induced by such immunogens
might be effective against majority of circulating viruses.
Analysis of molecular basis of the observed extensive cross-
neutralization of subtype C viruses from India and investigation
of immunogenic properties of these viruses may yield
information that could be useful in HIV-1 vaccine development
in a scenario of limited genetic diversity.
Materials and methods
Study subjects, blood sample collection and processing
Two hundred and thirty five HIV-1 seropositive individuals
(150 male and 85 female) enrolled in a study ‘Clinical
Progression of HIV Infection’, at National AIDS Research
Institute, Pune, India were included in the study. HIV
seropositivity was determined by commercial solid phase
combined ELISA for anti-HIV-1 and anti-HIV-2 antibodies
(Innotest HIV-1/HIV-2 Ab Immunogenetics, N.V. Zwijnarde,
Belgium; Genetic Systems HIV-1/HIV-2 EIA Sanofi Diagnos-
tics Pasteur, France; UBI HIV-1/HIV-2 EIA, United Biomedical
Co. Beijing, China), followed by a rapid test (HIV SPOT,
Genelabs Diagnostics, Singapore; HIV TRIDOT Biotech Inc,
Parwanoo, India) for all the samples that were positive in the
combined ELISA. All patients were HIV-1 infected for
unknown duration. Whole blood was collected in EDTA
vacutainers at the enrollment visit after obtaining written
informed consent. Plasma was aliquoted and stored at −70 °C
until tested. The study was approved by Ethics committee of the
Institute.
HIV-1 isolates
Thirteen primary HIV-1 subtype C isolates were obtained
from virus repository of National AIDS Research Institute,
Pune, India. Stocks of all viruses were developed using PBMCs
from a single donor. None of the virus was cultured more than
three times. Isolates were obtained from individuals that were
epidemiologically unlinked. The individuals were residents of
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Delhi) and were isolated at different time point (from year 1999
to 2005). The isolates from Maharashtra and Karnataka were
from different cities within these states. It was not possible to
determine time of infection in all patients except the isolate
26191, which was obtained within 1 month of seroconversion
from a male patient.
Estimation of CD4+ T cell count
CD4+ T lymphocyte percentages in freshly collected blood
samples were determined by flow cytometer using SimulSET
software (FACSort; Becton Dickinson Immunocytometry
Systems, San Jose, CA) after staining with phycoerythrin
labeled anti-CD4 antibody. Absolute CD4+ T cell counts were
calculated on the basis of total and differential blood cell
counts obtained by using automated hematology analyzer
(Sysmex KX 21).
Primary screening for detection of neutralizing antibody
response
Neutralization assay was performed using CCR5+ GHOST
cells that express Green Fluorescence Protein (GFP) under
control of HIV-1 Tat as described by Trkola et al. (1998). In
brief, virus (predetermined dilution that produces ∼1000
fluorescent cells at the end of the assay)–plasma mixture was
incubated at 37 °C for 1 h and was added to GHOST cells in the
presence of DEAE–dextran (8 μg/ml). The plate was incubated
at 37 °C with 5% CO2 and humidified atmosphere for 4 days.
After incubation, cells were harvested and analyzed on flow
cytometer (FACSort; Becton Dickinson). An electronic gate
was formed using forward and side scatter and within the gate
15,000 cells were acquired. Number of fluorescent cells was
determined after setting quadrants based on cells from
uninfected well. All plasma samples were heat-inactivated at
56 °C for 30 min before use. In primary screening, all plasma
samples (n=235) were tested at 1/10 dilution in duplicate
against a primary HIV-1 isolate, VB 49.
Plasma samples from 20 healthy, HIV seronegative indivi-
duals were also tested for background response at the same
dilution. Background response was 5.8±8.3% (mean±SD).
Neutralizing activity against a panel of primary isolates
Nineteen plasma samples that showed ≥90% neutralization
(≥1 log reduction in infectivity) against VB 49 in primary
screening were tested against a panel of 13 primary HIV-1
isolates (including the isolate used in primary screening). Six
two-fold dilutions of each plasma sample (from 1/10 to 1/320)
were tested against each virus from the panel.
Additionally two plasma samples that showed 50 to 60%
neutralization in primary screening were randomly selected and
were tested against a panel of 8 primary HIV-1 isolates (subset
of above 13 isolates) at 1/10 dilution.
Pool of plasma samples from 12 healthy, HIV seronegative
individuals was used as a negative control and was tested at 1/10dilution in each assay. The background response was <30% in
all assays.
Diversity among HIV-1 subtype C nucleotide sequences
HIV-1 subtype C gp120 nucleotide sequences from India,
Burundi, Botswana, South Africa, Tanzania and Zambia were
obtained from NIH Los Alamos HIV sequence database
(http://hiv-web.lanl.gov/components/hiv-db). When multiple se-
quences from same patient were available, one sequence per
patient was selected by using “one sequence/patient” mode at
search interface of HIV sequence database. There were 17
sequences from India, 8 from Burundi, 51 from Botswana, 180
from South Africa, 15 from Tanzania and 10 from Zambia. All
sequences from India, Burundi, Tanzania, Zambia and 17
randomly selected sequences from Botswana and South Africa
were analyzed for genetic diversity. The pairwise % genetic
divergence was determined using MegAlign program (DNAS-
TAR Inc). The % genetic divergence among sequences from
India was compared with divergence among sequences from
Burundi, Botswana, South Africa, Tanzania and Zambia by
Student's t-test.
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